- THE PROBLEM
- CHALLENGES OF TREATMENT
- FUTURE GOALS IN DIABETES
Intarcia Platform Technology
The DUROS device is a subcutaneous osmotic mini-pump. Each device contains an appropriate volume of drug product to treat a patient for a predetermined extended duration of time.
Exciting News About ITCA 650
December 13, 2011
Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
- Intarcia selects Quintiles as worldwide development partner; companies strike strategic alliance incorporating equity and product investments aligned with Phase 3 success
Executive Chairman Message
We aim to redefine health outcomes in serious diseases by building differentiated products with our breakthrough technology platform to:
- Enhance and optimize the benefit/risk profile of compounds
- Assure long-term adherence with dosing up to just once per year
- Deliver superior patient outcomes
